^
    7d
    A Multicenter Single-arm Prospective Clinical Study on First-line Treatment of Pancreatic Cancer Liver Metastases With Arterial Infusion Chemotherapy and Embolization Combined With Dual Immune Checkpoint Inhibitors. (clinicaltrials.gov)
    P2, N=38, Not yet recruiting, Shandong Provincial Hospital
    New P2 trial • Checkpoint inhibition
    |
    AiTan (rivoceranib) • albumin-bound paclitaxel
    7d
    A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC (clinicaltrials.gov)
    P2, N=120, Recruiting, GrandPharma (China) Co., Ltd.
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    10d
    PTC-Guided Therapy for Peritoneal Mesothelioma (clinicaltrials.gov)
    P=N/A, N=347, Recruiting, Beijing Tsinghua Chang Gung Hospital
    New trial
    |
    AiTan (rivoceranib) • oxaliplatin
    12d
    Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study (clinicaltrials.gov)
    P2, N=65, Not yet recruiting, First Affiliated Hospital of Chongqing Medical University
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • AiSuDa (ivarmacitinib)
    17d
    FAD-HCC-001: FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=86, Not yet recruiting, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
    New P2 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    17d
    SOP-XH-IRB: Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer (clinicaltrials.gov)
    P3, N=118, Not yet recruiting, Fujian Medical University
    New P3 trial
    |
    AiTan (rivoceranib) • AiRuiLi (adebrelimab)
    20d
    A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (clinicaltrials.gov)
    P3, N=687, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Jul 2024 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    21d
    Cocktail-001: A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2/3, N=222, Not yet recruiting, Shanghai Zhongshan Hospital
    New P2/3 trial
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib) • capecitabine • thalidomide
    22d
    Prior immunotherapy enhances survival outcomes of third-line apatinib treatment in advanced gastric cancer: A retrospective cohort study. (PubMed, Int J Cancer)
    Prior ICI therapy emerged as an independent favorable prognostic factor for survival in multivariate analysis. These findings suggest that prior ICI therapy may enhance the efficacy of subsequent third-line apatinib treatment in patients with advanced gastric cancer, providing important insights for optimizing treatment sequencing strategies in this setting.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    AiTan (rivoceranib)
    24d
    Identification and prioritization of high-frequency biomarkers and therapeutic targets in gastric cancer trials. (PubMed, BMC Cancer)
    By analyzing the clinical trial landscape and the safety and specificity of therapeutic targets for GC, this study offers a reference for future clinical investigation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • FGFR2 (Fibroblast growth factor receptor 2) • KDR (Kinase insert domain receptor) • CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Tyvyt (sintilimab) • AiTan (rivoceranib) • oxaliplatin
    1m
    Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (clinicaltrials.gov)
    P2, N=39, Recruiting, Hebei Medical University Fourth Hospital
    New P2 trial
    |
    AiTan (rivoceranib) • Qibeian (iparomlimab/tuvonralimab) • iparomlimab (QL1604)
    1m
    Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma. (PubMed, Sci Rep)
    Subsequently, we validated our findings using the STAT1 inhibitor fludarabine or the NK cell-depleting agent Asialo GM1. Furthermore, combination therapy remodeled the tumor microenvironment by reducing CA IX (hypoxia marker), CD31 (angiogenesis marker), and α-SMA (stromal activation marker) expression (p < 0.05). Apatinib enhances the efficacy and responsiveness of PD-1 inhibition via the STAT1/NK axis, while the combination therapy remodels the tumor microenvironment to potentiate anti-tumor effects.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CD31 (Platelet and endothelial cell adhesion molecule 1) • STAT1 (Signal Transducer And Activator Of Transcription 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    AiTan (rivoceranib) • fludarabine IV